WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018007592) NEW DOSAGE REGIMENS FOR ANTIBODY DRUG CONJUGATES BASED ON ANTI-AXL ANTIBODIES
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2018/007592    International Application No.:    PCT/EP2017/067101
Publication Date: 11.01.2018 International Filing Date: 07.07.2017
IPC:
C07K 16/28 (2006.01), A61P 35/00 (2006.01), A61K 47/68 (2017.01)
Applicants: GENMAB A/S [DK/DK]; Kalvebod Brygge 43 1560 Copenhagen V (DK)
Inventors: FORSSMANN, Ulf; (DE).
LISBY, Steen; (DK).
LOSIC, Nedjad; (SE)
Agent: GENMAB A/S; Kalvebod Brygge 43 1560 Copenhagen V (DK)
Priority Data:
62/410,984 21.10.2016 US
PCT/EP2016/066353 08.07.2016 EP
Title (EN) NEW DOSAGE REGIMENS FOR ANTIBODY DRUG CONJUGATES BASED ON ANTI-AXL ANTIBODIES
(FR) NOUVEAUX RÉGIMES POSOLOGIQUES POUR CONJUGUÉS ANTICORPS-MÉDICAMENTS À BASE D'ANTICORPS ANTI-AXL
Abstract: front page image
(EN)An antibody-drug conjugate (ADC) based on an antibody binding to human AXL and pharmaceutical compositions comprising the ADC for use in the treatment of a cancer comprising administering to a subject a weekly dose of from about 0.45 mg/kg to about 2.0 mg/kg of the ADC once a week for three consecutive weeks followed by a one week resting period without any administration of the ADC so that each cycle time is 28 days including the resting period.
(FR)L'invention concerne un conjugué médicament-anticorps (ADC) basé sur un anticorps se liant à un AXL humain et des compositions pharmaceutiques comprenant l'ADC pour une utilisation dans le traitement d'un cancer comprenant l'administration au patient d'une dose hebdomadaire, comprise entre environ 0,45 mg/kg et environ 2,0 mg/kg de l'ADC, une fois par semaine pendant trois semaines consécutives, suivi d'une période de repos d'une semaine sans administration de l'ADC, de telle sorte que chaque durée de cycle est de 28 jours en incluant la période de repos.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)